Glucosuria: a counter intuitive treatment for diabesity

Henry RR Wiest-Kent TA Scheaffer L . Metabolic consequences of very low-calorie diet therapy in obese non-insulin-dependent diabetic and nondiabetic subjects. Diabetes 1986; 35: 155-64.

Wing RR Koeske R Epstein LH . Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med. 1987; 147: 1749-53.

Bailey CJ . Hypoglycaemic, antihyperglycaemic and antidiabetic Drugs. Diabetic Medicine 1992; 9: 482-3.

Bailey CJ Davies MJ . Pharmacological therapy of hypoglycaemia in type 2 diabetes mellitus. In Oxford textbook of endocrinology and diabetes. 2nd edn Wass JAH Stewart PM eds. Oxford University Press, Oxford. 2011 pp. 1779-95.

Day C . ADA-EASD diabetes guidance: individualised treatment of hyperglycaemia. Br J Diabetes Vasc Dis 2012; 12: 146-151

Perlmuter LC Flanagan BP Shah PH Singh SP . Glycemic control and hypoglycemia. Diabetes Care. 2008; 31: 2072–76.

Bailey CJ . Diabetes: Insulin plus metformin for T2DM—are there benefits? Nature Reviews Endocrinology 2012; 8: 449-50.

Dowling RJO Goodwin PJ Stambolic V . Understanding the benefit of metformin use in cancer treatment. BMC Medicine 2011, 9: 33 doi: 10.1186/1741-7015-9-33. http://www.biomedcentral.com/1741-7015/9/33. Acessed January 2013.

European Medicines Agency. Marketing authorisation, Forxiga. November 2012 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002322/human_med_001546.jsp&mid=WC0b01ac058001d124. Accessed January 2013.

Bailey CJ Day C . SGLT2 inhibitors: glucuretic treatment for type 2 diabetes. Br J Diabetes Vasc Dis 2010; 10: 193-9.

Summary of product characteristics. Dapagliflozin. http://www.medicines.org.uk/emc/ Accessed January 2013.

List JF Woo V Morales E Tang W Fiedorek FT . Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650-7.

Komoroski B Vachharajani N Feng Y . Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009; 85: 513-9. (Erratum in vol 85 pt5: 558).

Wilding JP Norwood P T’joen C . A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009; 32: 1656-62.

Zhang L Feng Y List J . Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab. 2010; 12: 510-6.

Ferrannini E Ramos SJ Salsali A . Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010; 33: 2217-24.

Bailey CJ Gross JL Pieters A . Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-33.

Kasichayanula S Chang M Hasegawa M . Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab. 2011; 13: 357-65.

Strojek K Yoon KH Hruba V . Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011; 13: 928-38.

Nauck MA Del Prato S Meier JJ . Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34: 2015-22.

Bailey CJ Aqbal N T’joen C List JF . Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab 2012: 14: 951-9.

Salsali A Rohwedder K Mansfield TA . Durability of dapagliflozin treatment response in patients with T2DM: 2-year results. ADA 2012 . Diabetes 2012; 61: suppl 1, Abs 1030-P, A264.

Bolinder J Ljunggren Ö Kullberg J . Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97: 1020-31.

Henry RR Murray AV Marmolejo MH . Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012; 66: 446-56.

Wilding JP Woo V Soler NG , Dapagliflozin 006 Study Group. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012; 156: 405-15.

Rosenstock J Vico M Wei L . Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012; 35: 1473-8.

Kasichayanula S Liu X Shyu WC . Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab. 2011; 13: 47-54.

Kasichayanula S Chang M Liu X . Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Adv Ther. 2012; 29: 163-77.

Pollack A . Diabetes Drug Dapagliflozin Rejected by F.D.A. Panel. New York Times July 19, 2011. http://www.nytimes.com/2011/07/20/business/diabetes-drug-dapagliflozin-rejected-by-fda-panel.html?_r=0 accessed January 2013.

European Medicines Agency. CHMP summary of positive opinion for Forxiga EMA/CHMP/259852/2012. http://www.emea.europa.eu/ accessed January 2013.

Bailey CJ . Interpreting adverse signals in diabetes drug development programs. Diabetes Care 2013 in press

Clinical trials.gov. http://clinicaltrial.gov/ct2/results?term=SGLT2%20inhibitors accessed January 2013.

Ohtake Y Sato T Kobayashi T . Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem. 2012; 55: 7828-40.

Foot C Perkovik V Neal B . Effects of SGLT2 inhibitors on cardiovascular outcomes. Diabetes Vasc Dis Res. 9:117-23.

UK Medicines information. http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=5088 Accessed January 2013.